Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
AYTU 
Aytu BioScience Inc (AYTU)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/07/2026: AYTU (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9.33
1 Year Target Price $9.33
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -25.37% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/07/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 27.71M USD | Price to earnings Ratio - | 1Y Target Price 9.33 |
Price to earnings Ratio - | 1Y Target Price 9.33 | ||
Volume (30-day avg) 1 | Beta 0.33 | 52 Weeks Range 0.95 - 3.06 | Updated Date 01/7/2026 |
52 Weeks Range 0.95 - 3.06 | Updated Date 01/7/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.23 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -20.52% | Operating Margin (TTM) -10.83% |
Management Effectiveness
Return on Assets (TTM) 0.61% | Return on Equity (TTM) -50.23% |
Valuation
Trailing PE - | Forward PE 3.69 | Enterprise Value 24092803 | Price to Sales(TTM) 0.44 |
Enterprise Value 24092803 | Price to Sales(TTM) 0.44 | ||
Enterprise Value to Revenue 0.38 | Enterprise Value to EBITDA 1.14 | Shares Outstanding 10188208 | Shares Floating 7039033 |
Shares Outstanding 10188208 | Shares Floating 7039033 | ||
Percent Insiders 5.41 | Percent Institutions 35.17 |
Upturn AI SWOT
Aytu BioScience Inc
Company Overview
History and Background
Aytu BioScience, Inc. was founded in 2013. The company has undergone significant transformation, shifting its focus from a medical device company to a biopharmaceutical company specializing in prescription therapeutics. Key milestones include strategic acquisitions and a rebranding to Aytu Therapeutics.
Core Business Areas
- Prescription Therapeutics: Aytu BioScience focuses on acquiring, developing, and commercializing novel prescription therapeutics. Their portfolio targets various medical needs, with a recent emphasis on areas like ADHD, urology, and potentially cardiovascular health.
- Pediatric-focused Respiratory Solutions: Historically, the company offered a portfolio of pediatric-focused respiratory products, though their strategic direction has increasingly shifted towards prescription therapeutics.
Leadership and Structure
Aytu BioScience operates with a management team led by its CEO and other key executives overseeing finance, operations, and commercial strategy. The organizational structure is typical for a biopharmaceutical company, with departments dedicated to research and development, sales, marketing, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Tarfox (formerly Natrol):: A prescription treatment for ADHD. Competitors include established ADHD medications from companies like Shire (now Takeda), Novartis, and Mallinckrodt. Specific market share data for Tarfox is not publicly disclosed but is a key focus area for revenue generation.
- Covis Pharmaceutical Portfolio (acquired):: This acquisition brought a portfolio of established prescription drugs, including those for urological conditions and potentially others. Competitors vary by specific drug within the portfolio but generally include major pharmaceutical players in those therapeutic areas.
- Adhansia XR: Another ADHD medication. Competitors are the same as for Tarfox.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and capital-intensive, characterized by rigorous research and development, lengthy clinical trials, and complex regulatory pathways. The market for prescription therapeutics is driven by unmet medical needs, aging populations, and advancements in medical science. The ADHD market, in particular, is substantial and growing.
Positioning
Aytu BioScience is positioned as a commercial-stage biopharmaceutical company focused on growing its prescription therapeutics business through strategic acquisitions and commercialization efforts. Their competitive advantage lies in their ability to identify and acquire promising late-stage or commercial products and leverage their sales infrastructure.
Total Addressable Market (TAM)
The TAM for Aytu BioScience's key therapeutic areas, such as ADHD and urology, is in the tens of billions of dollars globally. Aytu is positioned to capture a segment of this market through its targeted product offerings. Their ability to grow market share depends on successful product differentiation, effective marketing, and physician adoption.
Upturn SWOT Analysis
Strengths
- Established commercial infrastructure for prescription therapeutics.
- Acquisition strategy to expand product portfolio.
- Focus on growing therapeutic areas with significant market potential (e.g., ADHD).
- Experienced management team.
Weaknesses
- Reliance on acquisitions for growth may lead to integration challenges.
- Potential for significant debt from acquisitions.
- Competition from larger, well-established pharmaceutical companies.
- Historical profitability challenges.
Opportunities
- Expansion into new therapeutic areas through further acquisitions.
- Leveraging existing sales force to promote new products.
- Potential for partnerships and collaborations.
- Growth in the ADHD market.
Threats
- Intense competition from established pharmaceutical players.
- Drug pricing pressures and regulatory changes.
- Patent expirations and generic competition for acquired products.
- Failure of acquired products to meet sales expectations.
- Market acceptance and physician prescribing habits.
Competitors and Market Share
Key Competitors
- Takeda Pharmaceutical Company Limited (TAK)
- Novartis AG (NVS)
- Mallinckrodt plc (MNK)
- H. Lundbeck A/S (HLU)
- AbbVie Inc. (ABBV)
Competitive Landscape
Aytu BioScience operates in a highly competitive landscape dominated by larger pharmaceutical companies with extensive R&D budgets and established market presence. Aytu's competitive advantage lies in its agility and focused acquisition strategy, allowing it to target specific niches or underperforming assets within larger markets. However, it faces challenges in matching the scale and marketing power of its larger rivals.
Major Acquisitions
Covis Pharmaceutical
- Year: 2022
- Acquisition Price (USD millions): 370
- Strategic Rationale: To significantly expand its commercial-stage prescription pharmaceutical portfolio, particularly in urology and women's health, and to enhance its revenue base and market presence.
Neos Therapeutics
- Year: 2020
- Acquisition Price (USD millions): 40.3
- Strategic Rationale: To acquire the ADHD medications Adhansia XR and Cotempla XR-ODT, strengthening its position in the pediatric and adolescent central nervous system market.
Growth Trajectory and Initiatives
Historical Growth: Aytu BioScience's historical growth has been largely driven by its strategic acquisition of product portfolios. This approach has led to significant revenue increases, though often accompanied by increased debt and operational expenses.
Future Projections: Future growth projections for Aytu BioScience are expected to be contingent on the successful integration and commercialization of acquired assets, as well as potential new product development or acquisitions. Analyst estimates will provide insights into anticipated revenue and profitability trends.
Recent Initiatives: Recent initiatives have included the acquisition of Covis Pharmaceutical's portfolio, a significant step in expanding their prescription therapeutics business. The company continues to explore opportunities for further strategic acquisitions to bolster its product pipeline and commercial reach.
Summary
Aytu BioScience Inc. is a biopharmaceutical company strategically focused on acquiring and commercializing prescription therapeutics. The company has demonstrated a growth trajectory driven by significant acquisitions, particularly that of Covis Pharmaceutical, which has expanded its product portfolio and revenue streams. While this strategy has boosted top-line growth, it also introduces challenges related to debt management and intense market competition from established pharmaceutical giants. Aytu must continue to effectively integrate and commercialize its acquired assets to maintain its growth momentum and navigate the complexities of the pharmaceutical industry.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company investor relations websites
- SEC filings (10-K, 10-Q)
- Financial news outlets
- Industry research reports
Disclaimers:
This JSON output is generated based on publicly available information and AI analysis. It is intended for informational purposes only and does not constitute financial advice. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Market share data is estimated and may not be precise. Financial metrics are subject to change and may not reflect the most current reporting period.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aytu BioScience Inc
Exchange NASDAQ | Headquaters Denver, CO, United States | ||
IPO Launch date 2017-02-01 | CEO & Director Mr. Joshua R. Disbrow | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 82 | Website https://aytubio.com |
Full time employees 82 | Website https://aytubio.com | ||
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.